drugset / Trial / NCT00642421
Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety profile of a new prolonged release formulation of octreotide acetate, C2L-OCT-01 PR, administered intra muscularly every 4, 5 or 6 weeks in acromegalic patients.
Timeline
- Start
- 2008-02
- Primary completion
- 2009-08
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | C2L-OCT-01 PR | Unknown | 10 mg | Intramuscular |
| Subject | C2L-OCT-01 PR | Unknown | 20 mg | Intramuscular |
| Subject | C2L-OCT-01 PR | Unknown | 30 mg | Intramuscular |